Company Description
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer.
The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic.
Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population.
The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML.
Notable Labs, Ltd. is headquartered in Foster City, California.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Thomas A. Bock M.B.A., M.D. |
Contact Details
Address: 320 Hatch Drive Foster City, California 94404 United States | |
| Phone | 415-851-2410 |
| Website | notablelabs.com |
Stock Details
| Ticker Symbol | NTBL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603207 |
| ISIN Number | IL0012002452 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas A. Bock M.B.A., M.D. | Chief Executive Officer and Director |
| Scott Alan McPherson CFE, CPA, CVA | Chief Financial Officer |
| Dr. Joseph P. Wagner Ph.D. | Chief Scientific Officer |
| Dr. Glenn C. Michelson M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 12, 2024 | 8-K | Current Report |
| Apr 11, 2024 | 10-K | Annual Report |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 16, 2024 | DEF 14A | Other definitive proxy statements |